Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsBlends & Stacks8 : 1 to 10 : 1 Ratio (Separate Vials) Blend / StackFemale-friendly

Retatrutide + Cagrilintide (Reta + Cagri)

Also known as: Reta + Cagri Stack, Triple Agonist + Amylin Stack (4-Receptor Protocol), Tirz / Reta + Cagri Plateau Stack

Dose Range
2–4 mgResearch range
0Typical research window: 2–4 mg5 mg

Studied in published research — not a medical recommendation. Primary protocol (Staggered Separate-Vial 8:1 Protocol): 2.0–4.0 mg Retatrutide (Monday) + 0.25–0.50 mg Cagrilintide (Thursday), Weekly (staggered 3.5 days apart).

Protocol at a Glance
How Often
2–3× weekly

Weekly (staggered 3.5 days apart)

A Typical Run
12–24 weeks

Research-reported range (no primary dosing study). Keep Retatrutide and Cagrilintide in separate vials so Cagrilintide stays at 0.25–0.5 mg while Retatrutide titrates from 2 mg -> 4 mg -> 6 mg

How It's Taken
Vial

Subcutaneous injection (separate syringes)

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

10 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 5 mg in every mL (50 mcg per unit)
0u10u20u30u40u50u
Low end: 2 mg40 units
High end: 4 mg80 units

All U-100: 100 units = 1 mL. 5 doses in the vial at the low end (2 doses at the high end).

Track the doses you run

Save Retatrutide + Cagrilintide (Reta + Cagri) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

Retatrutide + Cagrilintide (Reta + Cagri) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$80.00
15mg vial
$5.33/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Research / Non-FDATier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Incretin / Dual / Triple Metabolic Receptor Agonist (GLP-1 / GIP / Glucagon / Amylin)
Administration Route
Under-the-skin injection (Subcutaneous injection (separate syringes))
2026 FDA & 503A Status
Unapproved investigational compound in the US; not listed on the FDA 503A Bulk Drug Substances positive list. Available for laboratory research with third-party HPLC + LC-MS COA verification.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a GLP-1 Agonist?

A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.

Bottom Line Up Front

Because Retatrutide's glucagon receptor activity boosts basal metabolic rate with gentler early appetite suppression than Tirzepatide, researchers frequently layer low-dose Cagrilintide (0.25–0.5 mg/week) in an 8:1 to 10:1 separate-vial ratio (e.g., 2–4 mg Retatrutide + 0.25–0.5 mg Cagrilintide staggered 3.5 days apart).

Best evidence for

Published preclinical & translational clinical protocols

Weakest evidence for

Large multi-year outcomes in healthy non-clinical cohorts

Pharma equivalent

None

Studies on file

3 (0 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Retatrutide + Cagrilintide (Reta + Cagri) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

The Retatrutide + Cagrilintide ('Reta + Cagri') stack combines Eli Lilly's triple incretin/glucagon agonist (GLP-1R / GIPR / GCGR) with Novo Nordisk's long-acting amylin analog (Cagrilintide) for a 4-receptor metabolic protocol. While Retatrutide drives unmatched hepatic fat oxidation and resting energy expenditure via glucagon agonism, some users transitioning from high-dose Tirzepatide notice more 'food noise' at early Retatrutide doses (2–4 mg). Layering 0.25–0.5 mg of Cagrilintide mid-week restores potent amylin-mediated satiety without needing to push Retatrutide to high doses prematurely.

Mechanisms of Action

  • Retatrutide activates GLP-1, GIP, and Glucagon receptors to increase hepatic lipid oxidation and resting energy expenditure
  • Cagrilintide activates hindbrain amylin (AMY1–3) and calcitonin receptors to provide rapid meal termination and curb food noise
  • 4-receptor coverage (GLP-1R + GIPR + GCGR + AMYR) targets both caloric intake and thermogenic output

Common Ratios, Vial Formats & Dosing Breakdown

Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.

Open in Blend Calculator
8 : 1 to 10 : 1 Ratio (Separate Vials)

8:1 to 10:1 Separate-Vial Staggered Stack (Recommended)

Vial / Stack Breakdown

10mg Retatrutide vial + 5mg Cagrilintide vial (separate)

Typical Dosing & Syringe Draw

2.0–4.0 mg Retatrutide (Day 1) + 0.25–0.50 mg Cagrilintide (Day 4)

Why this ratio: Staggering injections by 3.5 days smooths appetite control across the entire week and allows independent titration of each compound.

1 : 1 Ratio (Use Caution)

1:1 Pre-Mixed Blend Vial (Ratio Warning)

Vial / Stack Breakdown

5mg Retatrutide / 5mg Cagrilintide (10mg total)

Typical Dosing & Syringe Draw

Only suitable at 0.25–0.5 mg starting doses

Why this ratio: Warning: A 1:1 pre-mixed Reta/Cagri vial locks both compounds together. Drawing 4 mg of Retatrutide from a 1:1 vial would deliver 4 mg of Cagrilintide (8x–16x the typical 0.25–0.5 mg Cagri dose), causing severe GI stasis and lethargy.

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Staggered Separate-Vial 8:1 Protocol
reported protocol
2.0–4.0 mg Retatrutide (Monday) + 0.25–0.50 mg Cagrilintide (Thursday)Weekly (staggered 3.5 days apart)12–24 weeksSubcutaneous injection (separate syringes)human—
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (Retatrutide + Cagrilintide (Reta + Cagri))

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Do NOT use a 1:1 pre-mixed vial once Retatrutide dose exceeds 0.5–1.0 mg/week; always use separate vials
  • •Ensure high protein intake (1.6g+/kg) and electrolyte hydration due to combined satiety + glucagon diuresis
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Retatrutide + Cagrilintide (Reta + Cagri), baseline labs & clinician oversight.

Full Retatrutide + Cagrilintide (Reta + Cagri) $/mg comparison →
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy Retatrutide + Cagrilintide (Reta + Cagri): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Elite Research USA — $5.33/mg (15mg vial, $80.00)

Where is the cheapest place to buy Retatrutide + Cagrilintide (Reta + Cagri)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Elite Research USA at $5.33/mg (15mg vial, $80.00). We compared 1 US supplier with live, checked prices.

How much does Retatrutide + Cagrilintide (Reta + Cagri) cost per mg?

Verified US domestic prices currently range from $5.33/mg to $5.33/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is Retatrutide + Cagrilintide (Reta + Cagri) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.